Overall, these findings show that KPNA2 overexpression in breast cancer leads to poor patient survival outcomes across multiple endpoints, demonstrating the prognostic value of KPNA2 as a potential biomarker and actionable target. This evidence concerns the gene KPNA2 and breast carcinoma.